REFLUDAN [lepirudin (rDNA) for injection]: the first direct thrombin inhibitor FDA-approved for heparin induced thrombocytopenia (HIT)

Learn more about the benefits of REFLUDAN
This section contains REFLUDAN laboratory and clinical efficacy data
This section contains information regarding the safe administration of REFLUDAN for the treatment of heparin induced thrombocytopenia (HIT)
This section describes the dosage and administration of REFLUDAN in the treatment of heparin induced thrombocytopenia (HIT)
Heparin induced thrombocytopenia
A summary of pivotal trial data for REFLUDAN is covered in this section
This section provides access to a variety of resources to obtain in-depth information on heparin induced thrombocytopenia (HIT) and REFLUDAN
Suggested Reading
Links
Dosing Calculator
Find out what your peers are saying about heparin induced thrombocytopenia (HIT)...

©2007 Bayer Healthcare Pharmaceuticals Inc. All rights reserved.

H.I.T. BACK with REFLUDAN to protect life and limb
Links
Associations



American Society of Hematology (ASH)
www.hematology.org

American Society of Health-System Pharmacists (ASHP)
www.ashp.org

American College of Cardiology (ACC)
www.acc.org

American Association of Critical-Care Nurses (AACN)
www.aacn.org

Society of Critical Care Medicine (SCCM)
www.sccm.org

Publications



Blood
www.bloodjournal.org

Circulation
www.circ.ahajournals.org

Formulary
www.formularyjournal.com

PDR
www.pdr.net

Pharmacy and Therapeutics
http://www.medirect.com/~cgilib/journal.asp?subj=phar&journal=jcpt

Other



Berlex Home Page
www.pharma.bayer.com



Suggested Reading
Links
Dosing Calculator
Terms of Use      Privacy Policy      About Our New Company
Bayer Healthcare Pharmaceuticals